Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protara Therapeutics (TARA) Gains from Sales and Divestitures (2021 - 2025)

Protara Therapeutics' Gains from Sales and Divestitures history spans 6 years, with the latest figure at $130411.0 for Q4 2025.

  • Quarterly Gains from Sales and Divestitures rose 16.88% to $130411.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $130411.0 through Dec 2025, up 16.88% year-over-year, with the annual reading at $130411.0 for FY2025, 16.88% up from the prior year.
  • Gains from Sales and Divestitures came in at $130411.0 for Q4 2025, roughly flat from $130411.0 in the prior quarter.
  • In the past five years, Gains from Sales and Divestitures ranged from a high of $188915.0 in Q4 2021 to a low of $30163.0 in Q4 2022.
  • The 5-year median for Gains from Sales and Divestitures is $111579.0 (2024), against an average of $115480.2.
  • Year-over-year, Gains from Sales and Divestitures plummeted 84.03% in 2022 and then soared 213.39% in 2023.
  • Protara Therapeutics' Gains from Sales and Divestitures stood at $188915.0 in 2021, then tumbled by 84.03% to $30163.0 in 2022, then skyrocketed by 213.39% to $94528.0 in 2023, then grew by 18.04% to $111579.0 in 2024, then rose by 16.88% to $130411.0 in 2025.
  • Per Business Quant, the three most recent readings for TARA's Gains from Sales and Divestitures are $130411.0 (Q4 2025), $130411.0 (Q3 2025), and $130411.0 (Q2 2025).